Moolec Science S.A. (MLEC) vs Processa Pharmaceuticals, Inc. (PCSA)
A side-by-side comparison of Moolec Science S.A. and Processa Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MLEC
Moolec Science S.A.
$4.77HealthcareDelayed quote: Oct 6, 2026, 2:36 PM EDT
PCSA
Processa Pharmaceuticals, Inc.
$1.49HealthcareDelayed quote: Oct 6, 2026, 2:18 PM EDT
Total return — MLEC vs PCSA
growth of $100 · dividends reinvested · last 6yMLEC -99.7% (-61.4%/yr)PCSA -100.0% (-74.7%/yr)MLEC compounded faster over this window
Log scale — wide-divergence pair
MLEC PCSA
MLEC vs PCSA: by the numbers
- •PCSA is the larger company ($4M vs $3M market cap).
- •Both run net losses; PCSA's is the smaller (0.00% vs -105.71% net margin).
Metrics side by side
Profitability
| Metric | MLEC | PCSA |
|---|---|---|
| Gross margin | 34.17% | 0.00% |
| Operating margin | -3.14% | 0.00% |
| Net margin | -105.71% | 0.00% |
| ROE | -89.85% | N/A |
| ROIC | -33.50% | N/A |
Growth (annualized)
| Metric | MLEC | PCSA |
|---|---|---|
| Total return CAGR (5Y) | -68.13% | -79.32% |
Frequently asked
- How have MLEC and PCSA total returns compared?
- Over the past 5 years, MLEC delivered -68.13% and PCSA delivered -79.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.